(secondQuint)Pilot Study of Patient's Adherence to TYKERB/TYVERB + Capecitabine in Metastatic Breast Cancer.

 Approximately 60 subjects with HER2+ metastatic or advanced breast cancer who meet the inclusion/exclusion criteria will be enrolled into the study.

 All subjects will receive education intervention for 6 weeks including education on Day 0, follow-up phone calls on Day 1 and Day 7, reminder phone calls before Week 3 and 6 visit and telephone hot line number.

.

 Pilot Study of Patient's Adherence to TYKERB/TYVERB + Capecitabine in Metastatic Breast Cancer@highlight

This is a 6-week, single arm, pilot study to test the study procedure, educational materials, and measurement instruments for the educational intervention in HER2 overexpressing metastatic or advanced breast cancer patients